Status:
TERMINATED
Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 1
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This trial is conducted in Europe and North America. The aim of this trial is to investigate if liraglutide treatment can increase the proportion of insulin-independent subjects one year after islet c...
Eligibility Criteria
Inclusion
- Type 1 diabetes mellitus for at least 5 years
- Candidate for islet cell transplantation based upon local accepted practice and guidelines
- Reduced awareness of hypoglycaemia
Exclusion
- Treatment with any anti-diabetic medication other than insulin including insulin pump within 4 weeks of trial start
- Any previous organ transplantation
- A history of acute idiopathic or chronic pancreatitis
- Family or personal history of multiple endocrine neoplasia type 2 (MEN2) or familial medullary thyroid carcinoma (FMTC)
Key Trial Info
Start Date :
March 21 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 3 2013
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT01206101
Start Date
March 21 2012
End Date
June 3 2013
Last Update
March 30 2017
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Duarte, California, United States, 91010
2
Novo Nordisk Investigational Site
Chicago, Illinois, United States, 60612
3
Novo Nordisk Investigational Site
Boston, Massachusetts, United States, 02114
4
Novo Nordisk Investigational Site
Madison, Wisconsin, United States, 53792-0001